MX2021002492A - Formulación antibiótica inyectable de liberación sostenida. - Google Patents
Formulación antibiótica inyectable de liberación sostenida.Info
- Publication number
- MX2021002492A MX2021002492A MX2021002492A MX2021002492A MX2021002492A MX 2021002492 A MX2021002492 A MX 2021002492A MX 2021002492 A MX2021002492 A MX 2021002492A MX 2021002492 A MX2021002492 A MX 2021002492A MX 2021002492 A MX2021002492 A MX 2021002492A
- Authority
- MX
- Mexico
- Prior art keywords
- antibiotical
- sustained
- formulation
- compositions
- release injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se proporcionan composiciones de antibióticos inyectables para uso veterinario. Las composiciones se caracterizan por formar un gel a la temperatura fisiológica animal, dicho gel se caracteriza por un perfil de liberación estable y repetible del antibiótico. Las composiciones comprenden una alta carga de fármaco en soluciones de poloxámero con la adición de un cosolvente, y preferentemente con una adición de un derivado de celulosa al menos parcialmente soluble en solventes orgánicos. También se proporcionan métodos de tratamiento de infecciones veterinarias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862727574P | 2018-09-06 | 2018-09-06 | |
PCT/IL2019/050998 WO2020049570A1 (en) | 2018-09-06 | 2019-09-05 | Sustained-release injectable antibiotical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002492A true MX2021002492A (es) | 2021-09-08 |
Family
ID=68072920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002492A MX2021002492A (es) | 2018-09-06 | 2019-09-05 | Formulación antibiótica inyectable de liberación sostenida. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210315803A1 (es) |
EP (1) | EP3846781A1 (es) |
JP (1) | JP2021536485A (es) |
KR (1) | KR20210099553A (es) |
CN (1) | CN113412109A (es) |
BR (1) | BR112021004192A2 (es) |
CA (1) | CA3111385A1 (es) |
CL (1) | CL2021000536A1 (es) |
CO (1) | CO2021004131A2 (es) |
EA (1) | EA202190672A1 (es) |
MX (1) | MX2021002492A (es) |
PE (1) | PE20211334A1 (es) |
PH (1) | PH12021550477A1 (es) |
WO (1) | WO2020049570A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306211B (zh) * | 2021-12-29 | 2023-12-22 | 中国药科大学 | 一种甘草酸超分子自组装温敏互穿网络凝胶及其制备方法和应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740421A (en) | 1966-09-19 | 1973-06-19 | Basf Wyandotte Corp | Polyoxyethylene-polyoxypropylene aqueous gels |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
CA2228118A1 (en) | 1995-07-28 | 1997-02-13 | Focal, Inc. | Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents |
US6316011B1 (en) | 1998-08-04 | 2001-11-13 | Madash, Llc | End modified thermal responsive hydrogels |
JP4644397B2 (ja) * | 2001-09-05 | 2011-03-02 | 信越化学工業株式会社 | 難溶性薬物を含む医薬用固形製剤の製造方法 |
GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
NZ555774A (en) * | 2004-12-21 | 2010-09-30 | Intervet Int Bv | Injectable veterinary composition comprising florfenicol, a pyrrolidone solvent and a cosolvent selected from diethyleneglycol monoethyl ether and / or tetrahydrofurfuryl alcohol polyethylene glycol ether |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
EP2490722A4 (en) * | 2009-10-21 | 2014-03-05 | Otonomy Inc | MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS |
US8614315B2 (en) * | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
CA2806208C (en) * | 2010-07-22 | 2018-02-13 | Zishan Haroon | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution |
BR112013024863A2 (pt) * | 2011-03-28 | 2016-12-20 | Yissum Res Dev Co | formulação injetável de liberação sustentada |
CN103202802A (zh) | 2013-04-22 | 2013-07-17 | 南京农业大学 | 氟苯尼考注射用原位凝胶及其制备方法 |
CA2989283A1 (en) * | 2015-06-16 | 2016-12-22 | Sun Pharma Advanced Research Company Limited | Long acting liraglutide compositions |
-
2019
- 2019-09-05 US US17/273,828 patent/US20210315803A1/en active Pending
- 2019-09-05 KR KR1020217010138A patent/KR20210099553A/ko active Search and Examination
- 2019-09-05 JP JP2021512900A patent/JP2021536485A/ja active Pending
- 2019-09-05 CN CN201980072403.8A patent/CN113412109A/zh active Pending
- 2019-09-05 EP EP19779197.3A patent/EP3846781A1/en active Pending
- 2019-09-05 PE PE2021000294A patent/PE20211334A1/es unknown
- 2019-09-05 CA CA3111385A patent/CA3111385A1/en active Pending
- 2019-09-05 BR BR112021004192-3A patent/BR112021004192A2/pt unknown
- 2019-09-05 WO PCT/IL2019/050998 patent/WO2020049570A1/en unknown
- 2019-09-05 MX MX2021002492A patent/MX2021002492A/es unknown
- 2019-09-05 EA EA202190672A patent/EA202190672A1/ru unknown
-
2021
- 2021-03-04 CL CL2021000536A patent/CL2021000536A1/es unknown
- 2021-03-05 PH PH12021550477A patent/PH12021550477A1/en unknown
- 2021-04-05 CO CONC2021/0004131A patent/CO2021004131A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021004131A2 (es) | 2021-07-30 |
PE20211334A1 (es) | 2021-07-22 |
EP3846781A1 (en) | 2021-07-14 |
CA3111385A1 (en) | 2020-03-12 |
CL2021000536A1 (es) | 2021-08-20 |
CN113412109A (zh) | 2021-09-17 |
JP2021536485A (ja) | 2021-12-27 |
KR20210099553A (ko) | 2021-08-12 |
EA202190672A1 (ru) | 2021-07-01 |
BR112021004192A2 (pt) | 2021-05-25 |
US20210315803A1 (en) | 2021-10-14 |
WO2020049570A1 (en) | 2020-03-12 |
PH12021550477A1 (en) | 2021-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
PH12017500720A1 (en) | Glycopeptide compositions | |
ECSP077239A (es) | Formulación farmacéutica | |
MX2020002841A (es) | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. | |
CL2014003215A1 (es) | Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion | |
CL2014003216A1 (es) | Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion. | |
BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
PH12021550477A1 (en) | Sustained-release injectable antibiotical formulation | |
JP2015532923A5 (es) | ||
CO2018008444A2 (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
CL2018001910A1 (es) | Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
AR105223A1 (es) | Compuestos químicos | |
NO20074262L (no) | Anthelmintisk sammensetning | |
NZ701697A (en) | Stable veterinary anthelmintic formulations | |
WO2016130800A3 (en) | Pharmaceutical compositions comprising perillyl alcohol derivatives | |
PT110634A (pt) | Ivermectina amorfa e processo para a sua produção | |
MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
AU2018260628A1 (en) | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | |
MX353876B (es) | Metodo para el tratamiento de una infeccion. | |
BR112015029260A2 (pt) | derivados de tilosina e seu método de preparação | |
BR112022004836A2 (pt) | Processo para preparar um hidrogel super poroso plastificado, uso de um ou mais hidrogéis super porosos plastificados e formulação de dosagem oral | |
WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
WO2018165477A8 (en) | Injectable antibiotic formulations and use thereof | |
AR074674A1 (es) | Combinacion de sustancias activas mejorada que comprende un antibiotico y un farmaco antiinflamatorio no esteroideo (aine) | |
EA202090809A1 (ru) | Высокодозовый состав валбеназина и композиции, способы и наборы, связанные с ним |